IαIp Purification Using Endotoxin-Binding Agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for purifying Inter-alpha Inhibitor Proteins (IαIps) from biological materials, such as blood, result in low yields and require complex stepwise extraction followed by chromatographic separations, which are inefficient and costly.
Innovation Solution
A method involving the use of an endotoxin-binding agent, like ETOXICLEAR™ or DETOXI-GEL™, to purify IαIps by applying biological materials to a chromatography column, utilizing specific buffers for separation and elution, thereby improving yield and purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If stepwise extraction followed by chromatographic separations is used, then purity of IαIps is improved (>90% purity), but yield is reduced (20-30% w/w)
Solution Approach 1:
The patent applies endotoxin-binding agents to specifically extract and remove endotoxins from biological materials containing IαIps. This selective extraction allows the IαIps to remain in the solution while endotoxins are bound and removed, thereby improving purity without requiring multiple chromatographic steps that would reduce yield.
Solution Approach 2:
Endotoxin-binding agents serve as intermediary substances that mediate the separation between IαIps and endotoxins. These agents bind specifically to endotoxins, acting as a bridge that enables selective removal of endotoxins while leaving IαIps intact in the solution, thus achieving high purity with minimal loss of target protein.
2Manufacturing precision
If stepwise extraction followed by chromatographic separations is used, then purity of IαIps is improved, but process complexity is increased
Solution Approach 1:
The patent combines endotoxin removal and IαIp purification into a single integrated step using endotoxin-binding agents. Instead of performing separate extraction and chromatographic separation steps, the endotoxin-binding agent simultaneously removes endotoxins and purifies IαIps in one operation, significantly simplifying the overall process.
Solution Approach 2:
The method extracts endotoxins specifically using endotoxin-binding agents, removing the need for complex multi-step chromatographic separations. This single extraction step achieves both endotoxin removal and IαIp purification, reducing process complexity while maintaining high purity.
3Manufacturing precision
If stepwise extraction followed by chromatographic separations is used, then purity of IαIps is improved, but time consumption is increased
Solution Approach 1:
The patent merges endotoxin removal and protein purification into a single simultaneous process using endotoxin-binding agents. This eliminates the need for sequential chromatographic steps, dramatically reducing the total time required while achieving the same purity level.
Solution Approach 2:
Endotoxin-binding agents act as intermediaries that enable rapid and selective endotoxin removal without requiring time-consuming chromatographic separations. The binding agents quickly capture endotoxins, allowing for fast purification of IαIps with high purity in minimal time.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enhances the yield of IαIps to greater than 20% and achieves high purity, simplifying the purification process while maintaining or increasing the biological activity of the proteins.
Implementation Method 1
applying a biological material containing an IαIp (e.g., blood or milk), such as a biological material obtained from a subject (e.g., a human), to an endotoxin-binding agent (e.g., a solid support, such as a chromatography column, containing an endotoxin-binding agent)
Implementation Method 2
applying an elution buffer comprising a salt to the endotoxin-binding agent and collecting an eluate comprising the IαIp
Data Source
AI summary
Described herein are methods for purifying IαIp from a biological material using an endotoxin-binding agent. The method involves applying the biological material containing the IαIp to an endotoxin-binding agent, discarding the flow through, applying a wash buffer(s), and eluting the IαIp from the endotoxin-binding agent.